Drug Discovery World

AUGUST 3, 2022

CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. Currently, only a small number of CPP-based oligonucleotide delivery examples have been reported for in vivo application.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

JULY 22, 2022

In vivo models, particularly HIS models, allow preliminary investigation of cell-based therapeutic strategies—often in combination with other therapeutic modalities—to overcome the limitations and challenges of T cell-based immuno-oncology treatments and identify effective options for clinical investigation. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

JANUARY 12, 2021

We are planning to manufacture doses for around two million patients in 2021 and hope to improve access to this treatment option for those that require.”. CT-P59 treatment groups also reported with significantly shortened time to clinical recovery ranging from 3.4 days quicker compared to placebo. days; 95% C.I, days compared to placebo [5.7

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vivo 40

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Delveinsight

JANUARY 12, 2021

The companies believe that their candidate in its original IgG format has shown potent neutralization activity in in vitro assays and in an in vivo animal model. Thus, the company decided to separately focus on different units and make better decisions for commercial manufacturing. and Europe.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.

Antibody 52

Antibody Licensing Licensing Development 52

Pharmaceutical Technology

MAY 31, 2023

In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases. The agreement will cover the Hong Kong special administrative region (SAR), the Macau SAR and Taiwan.

Bioavailability 130

Bioavailability In-Vivo In-Vitro Licensing 130

The Pharma Data

OCTOBER 22, 2020

The drug is now widely available in hospitals across the country, following early investments to rapidly expand manufacturing capacity to increase supply. Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 13, 2022

However, this discovery is being accomplished with help from contract development and manufacturing organisations (CDMOs) – compelled by the vaccine’s developers to expand capability to support vaccine development during pandemics. . One aspect that makes mRNA technology popular with drug developers is that its proteins can be easily edited.

Drugs 52

Drugs Manufacturing Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 1, 2024

From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. Time can mean more than money when you’re studying a deadly pathogen. When all is said and done, this process may take months or years to complete.

Antibody 64

Antibody Gene Protein Manufacturing 64

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Luncheon presentations will be given by Andrew Bradbury, MB BS, PhD, Chief Scientific Officer, Specifica, and Stefanie Kall, Ph.D.,

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

JANUARY 23, 2023

This circumvents several technical challenges inherent to the genetic manipulation of differentiated cells in ex vivo culture or intact tissues. These cells present a highly scalable platform, capable of manufacturing advanced cellular therapeutics.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

MAY 10, 2023

Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Drug discovery and development New pharmaceutical small molecule drugs require extensive safety testing before the manufacturer can obtain regulatory approval for use in humans.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. Alloy’s first platform, the ATX-Gx(TM) mouse platform, is a suite of transgenic mice designed for best-in-class in vivo discovery of fully human monoclonal antibodies.

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Many compounds present sub-optimal pharmacokinetic (PK) data (either predicted from in-vitro and pre-clinical data or measured in the clinic), such as poor exposure (leading to high doses), large variability, short half-life requiring more than once-a-day dosing, or C max -related adverse events (AEs).

Development 246

Development Drugs Bioavailability In-Vivo 246